Pediatric Combo Drugs Could Rely On Individual Active Ingredient Studies
Executive Summary
FDA may allow sponsors of combination drugs to rely on data from studies of individual drug components for pediatric submissions.
You may also be interested in...
Wyeth Sonata Short-Term Psychomotor Symptoms Allows Mid-Night Dosing
The short-term psychomotor effects of Wyeth-Ayerst's insomnia drug Sonata (zaleplon) allow late night dosing without significant lingering effects the following day.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011